Radiation Therapy and Targeted Therapies for Pancreatic Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 1196

Editor


E-Mail Website
Guest Editor
Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada
Interests: GI malignancies; breast cancer; SBRT; cell signalling; immunotherapy and radiation; radiobiology

Special Issue Information

Dear Colleagues,

Pancreatic cancers are associated with poor survival and although treatment approaches have evolved considerably in the last few years, the prognosis continues to be dismal. Since most patients present with advanced disease, as well as because the biology of these cancers are associated with early metastases, the treatment focus has mainly been on systemic therapies. That said, diagnosis and treatment at an early stage when the disease is localized is associated with a considerable improvement in survival and while systemic treatments continue to be the cornerstone for management of pancreatic cancer, for localized and non-metastatic disease, local treatments including surgery and radiation may play a significant role in disease control and potentially even cure in some patients. Much effort is also going into exploring novel treatment strategies that target pathways or molecular signatures that may be characteristic of pancreatic cancers and can be exploited to give better disease control both by themselves and in combination with other conventional treatment strategies.

Radiation therapy has been a part of the canonical treatment arsenal for pancreatic cancers and has been evaluated as a treatment option both on its own as well as in conjunction with systemic therapy, with reports showing varying outcomes. Interest in radiation as a treatment modality has continued despite occassional conflicting outcomes. Recent efforts have also seen the development of therapeutics that target various signaling and molecular pathways and there appears to be a lot of promise as noted both in the preclinical and early human trials. This Special Issue aims to collate as much evidence as possible that specifically looks at the role of radiation therapy in pancreatic cancers, especially in the era of advanced radiotherapy techniques. Along with radiation, this Special Issue will also aim to bring together evidence on targeted therapies currently being explored or in the process of development for the treatment of these cancers.

I/We look forward to receiving your contributions.

Dr. Aswin Abraham
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • radiation
  • chemo-radiation
  • SBRT
  • patterns of failure
  • radiobiology
  • radiation techniques
  • cell signaling
  • immunotherapy and radiation
  • targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 553 KB  
Article
Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis
by Colin Faulkner, Ayah Erjan, Sara Mheid, Michael Yan, Chaya Ganor Shwaartz, Erica Tsang, Sangeetha Kalimuthu, Teodor Stanescu, Ali Hosni and Aruz Mesci
Curr. Oncol. 2026, 33(6), 337; https://doi.org/10.3390/curroncol33060337 - 6 Jun 2026
Viewed by 740
Abstract
Isolated Locoregionally Recurrent Pancreatic Adenocarcinoma (ILRPA) accounts for 25–30% of recurrences after radical resection, yet the role of salvage radiation (RT) in this setting remains controversial due to limited data. We aimed to evaluate the impact of salvage RT on survival outcomes compared [...] Read more.
Isolated Locoregionally Recurrent Pancreatic Adenocarcinoma (ILRPA) accounts for 25–30% of recurrences after radical resection, yet the role of salvage radiation (RT) in this setting remains controversial due to limited data. We aimed to evaluate the impact of salvage RT on survival outcomes compared with non-salvage RT in patients with ILRPA. We retrospectively analyzed data of patients with ILRPA post-radical resection treated at our centre between 2012 and 2021. Patients were categorized into two cohorts based on whether salvage RT was administered post-recurrence. Patients who received a minimum of 30 Gy in 10 fractions (BED10 ≥ 39 Gy) were included for analysis. The clinical characteristics, treatments, and outcomes were analyzed. The chi-square or Fisher’s exact test for categorical variables and Student’s t-test or Wilcoxon rank sum test for continuous variables were utilized for comparisons. The Kaplan–Meier method and log-rank test were performed to compare overall survival (OS) and progression-free survival (PFS) between the two groups. OS and PFS were calculated from the time of locoregional recurrence until event or loss of follow-up. Thirty-two patients were identified, with sixteen patients in each group. The patients and tumour characteristics were balanced between the two cohorts, except for chemotherapy, where the salvage RT group tended to receive palliative chemotherapy more than the non-salvage group (p = 0.007). The median radiotherapy dose received for the salvage RT cohort was 50.4 Gy (BED10 = 59.5 Gy). Chemotherapy was restarted in 75% either before, after, or during radiation, and only in 31.25% of patients in the non-salvage group (p = 0.013). Patients who received salvage RT had statistically significantly better median OS and PFS than those who did not (25.2 vs. 8.4 months, p = 0.0006, HR 0.25, 95% CI (0.11–0.59)), (15.6 vs. 7.2 months, p = 0.0006, HR 0.26, 95% CI (0.11–0.58), respectively). Ten patients (62.5%) developed distant metastases (DM) at least 3 months post-recurrence in the salvage RT cohort compared to five patients (31.25%) in the non-salvage RT cohort (p = 0.08). In the salvage RT group, 10/16 patients (62.5%) maintained locoregional disease control post-RT. Salvage RT was associated with better OS and PFS in patients with ILRPA, highlighting its potential as an essential treatment modality. While salvage RT appears beneficial, confounding factors like chemotherapy disparities between groups necessitate further investigation in prospective cohorts. Full article
(This article belongs to the Special Issue Radiation Therapy and Targeted Therapies for Pancreatic Cancer)
Show Figures

Figure 1

Back to TopTop